Chemomab Therapeutics
CMMB
12 hedge funds and large institutions have $3.34M invested in Chemomab Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.04% less ownership
Funds ownership: 0.33% → 0.29% (-0.04%)
14% less funds holding
Funds holding: 14 → 12 (-2)
27% less capital invested
Capital invested by funds: $4.58M → $3.34M (-$1.24M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$4.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$458K |
| 2 |
Two Sigma Investments
New York
|
-$48.1K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$36.8K |
| 4 |
Two Sigma Advisers
New York
|
-$18.8K |
| 5 |
Morgan Stanley
New York
|
-$12.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $2.95M | – | – | – |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $280K | -$36.8K | -5,829 | -10% |
|
|
KPWS
3
Kestra Private Wealth Services
Austin,
Texas
| $41.1K | – | – | – |
|
|
BFM
4
Boothbay Fund Management
New York
| $34.9K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $15.4K | – | – | – |
|
|
ASN
6
Advisory Services Network
Atlanta,
Georgia
| $14.7K | – | – | – |
|
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $3.94K | +$4.74K | +751 | New |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $3.58K | – | – | – |
|
|
NFSG
9
Newbridge Financial Services Group
Boca Raton,
Florida
| $1.45K | – | – | – |
|
|
10
Morgan Stanley
New York
| $132 | -$12.1K | -1,925 | -99% |
|
11
UBS Group
Zurich,
Switzerland
| $16 | -$631 | -100 | -97% |
|
|
CAM
12
Cormorant Asset Management
Boston,
Massachusetts
| – | -$458K | -72,042 | Closed |
|
|
13
Two Sigma Investments
New York
| – | -$48.1K | -7,566 | Closed |
|
|
14
Two Sigma Advisers
New York
| – | -$18.8K | -2,950 | Closed |
|
CMMB Hedge Fund Activity: Q2 2023 in Review
12 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2023, worth a combined $3.34M — down 27% from $4.58M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CMMB and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $4.74K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $458K sold.
- 12 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2023, down from 14 in Q1 2023.
- Funds reported $3.34M of Chemomab Therapeutics stock for Q2 2023, down 27% quarter-over-quarter.
- 1 fund opened new Chemomab Therapeutics positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Chemomab Therapeutics buyer in Q2 2023 was RhumbLine Advisers, an estimated $4.74K added.
- The largest Chemomab Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $458K sold.
Based on aggregated 13F filings for Q2 2023.